Wilson Sonsini Goodrich & Rosati represented Forte Biosciences in the transaction.Forte Biosciences (NASDAQ: FBRX) announced key R&D updates for its product candidate FB-102 (a proprietary molecule with…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
